Omnicell Reports 15% Revenue Increase

By Chris Stiles • Tuesday, April 28 11:43 • Permanent Link

Omnicell reported first-quarter 2026 revenue of $310 million, up $40 million, or 15%, from $270 million a year earlier.

The company swung to a GAAP profit of $11 million, or $0.25 a diluted share, from a GAAP loss of $7 million, or $0.15 a share, in the first quarter of 2025.

On a non-GAAP basis, net income rose to $25 million, or $0.55 a share, from $12 million, or $0.26 a share, a year ago. Non-GAAP EBITDA nearly doubled to $45 million from $24 million.

Cash from operating activities increased to $55 million from $26 million in the prior-year quarter. Omnicell ended March 31 with $239 million in cash and cash equivalents, $168 million of debt, and $350 million of availability on its revolving credit facility.

Revenue growth came from connected devices, technical services, SaaS and expert services, and consumables. The company said demand was strong across its core points-of-care solutions.

For the second quarter, Omnicell guided to revenue of $307 million to $313 million, with product revenue of $174 million to $177 million and service revenue of $133 million to $136 million. For full-year 2026, it projected revenue of $1.215 billion to $1.255 billion, product revenue of $690 million to $710 million, and service revenue of $525 million to $545 million.

Omnicell raised its full-year 2026 non-GAAP EBITDA guidance to $153 million to $168 million and its non-GAAP EPS outlook to $1.80 to $2.00. It also forecast annual recurring revenue of $680 million to $700 million and product bookings of $510 million to $560 million. Following these announcements, the company's shares moved 2.75%, and are now trading at a price of $37.37. For the full picture, make sure to review OMNICELL, INC.'s 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.